Athena Athena

X

Find Radio Compass News for Bupropion

PharmaCompass
API SUPPLIERS
API Suppliers

API Suppliers

US DMFs Filed

US DMFs Filed

CEP/COS Certifications

CEP/COS Certifications

0

JDMFs Filed

JDMFs Filed

0

Other Certificates

Other Certificates

Other Suppliers

Other Suppliers

API REF. PRICE (USD / KG)
65
INTERMEDIATES
DOSSIERS // FDF
USA (Orange Book)

USA (Orange Book)

Europe

Europe

Canada

Canada

Australia

Australia

South Africa

South Africa

Uploaded Dossiers

Uploaded Dossiers

GLOBAL SALES (USD Million)

U.S. Medicaid

Annual Reports

EXCIPIENTS
PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

News

REF STANDARD

EDQM

0

USP

JP

0

Other Listed Suppliers

SERVICES
left grey arrow
right gray arrow
  • TABLET;ORAL - 100MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - 50MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET;ORAL - 75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - 90MG;8MG
  • TABLET, EXTENDED RELEASE;ORAL - 100MG
  • TABLET, EXTENDED RELEASE;ORAL - 150MG
  • TABLET, EXTENDED RELEASE;ORAL - 200MG
  • TABLET, EXTENDED RELEASE;ORAL - 150MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
  • TABLET, EXTENDED RELEASE;ORAL - 150MG
  • TABLET, EXTENDED RELEASE;ORAL - 300MG
  • TABLET, EXTENDED RELEASE;ORAL - 450MG

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf

FDA
13 Dec 2023

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-october-25-2023-66768.pdf

FDA
25 Oct 2023

https://www.pharmacompass.com/pdf/news/fda-confirms-paragraph-iv-patent-litigation-for-dextromethorphan-hydrobromide-and-bupropion-hydrochloride-extended-release-tablet-83509.pdf

FDA
23 Feb 2023

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-february-22-2023-51785.pdf

FDA
22 Feb 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216766

FDA
09 Jan 2023

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208043

FDA
29 Nov 2022

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-may-18-2022-1653024384.pdf

FDA
19 May 2022

https://axsometherapeuticsinc.gcs-web.com/news-releases/news-release-details/axsome-therapeutics-announces-publication-pivotal-ascend-phase-2

PRESS RELEASE
18 May 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=215568

FDA
02 Feb 2022

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210015

FDA
03 Jan 2022

https://www.prnewswire.com/news-releases/currax-pharmaceuticals-announces-the-appointment-of-ed-cinca-to-senior-vice-president-global-marketing-and-strategic-alliance-management-301408090.html

PRNEWSWIRE
26 Oct 2021

https://www.pharmacompass.com/pdf/news/health-canada-issues-recall-of-sun-pharmas-taro-bupropion-xl-1632832436.pdf

Health Canada
13 Sep 2021

https://www.prnewswire.com/news-releases/nida-funded-study-evaluating-extended-release-injectable-naltrexone-plus-bupropion-for-the-treatment-of-methamphetamine-use-disorder-published-in-new-england-journal-of-medicine-301208061.html

PRNEWSWIRE
14 Jan 2021

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208606

FDA
16 Jan 2020

http://www.pharmabiz.com/NewsDetails.aspx?aid=117984&sid=2

PHARMABIZ
05 Sep 2019

https://www.businesswire.com/news/home/20190905005353/en

BUSINESSWIRE
03 Sep 2019

https://www.patentdocs.org/2019/08/nalproprion-pharmaceuticals-inc-v-actavis-laboratories-fl-inc-fed-cir-2019.html

Kevin E. Noonan PATENT DOCS
22 Aug 2019

https://www.gov.uk/drug-safety-update/naltrexone-bupropion-mysimba-risk-of-adverse-reactions-that-could-affect-ability-to-drive

GOVUK
19 Aug 2019

https://www.biospace.com/article/how-the-pharmaceutical-industry-is-looking-to-treat-low-sex-drive/

Sasha Mortimer BIOSPACE
10 Jul 2019

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211020

FDA
28 Jan 2019

https://www.firstwordpharma.com/node/1612729#axzz5aLzPQQis

FIRSTWORDPHARMA
19 Dec 2018

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-november-14-2018-1542217134.pdf

FDA
14 Nov 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210497

FDA
03 Nov 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=211347

FDA
19 Oct 2018

https://www.accessdata.fda.gov/scripts/ires/index.cfm?action=print.getPrintData&ts=8262018111931

FDA
26 Sep 2018

https://www.forbes.com/sites/joshuacohen/2018/09/10/belviq-study-results-may-improve-the-fortunes-of-weight-loss-drugs/#2cefd3836a40

Joshua Cohen FORBES
11 Sep 2018

https://www.pharmacompass.com/pdf/news/Enforcement-Report-Week-of-August-22-2018-1534903909.pdf

FDA
22 Aug 2018

https://www.fiercepharma.com/marketing/eisai-obesity-drug-belviq-picks-up-edge-long-awaited-heart-safety-data

Carly Helfand FIERCE PHARMA
19 Jul 2018

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=203013

FDA
11 Jun 2018

http://www.pharmabiz.com/NewsDetails.aspx?aid=109403&sid=2

PHARMABIZ
11 Jun 2018

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-11-2018-1523421880.pdf

FDA
11 Apr 2018

https://endpts.com/with-debt-looming-browbeaten-diet-pill-maker-orexigen-goes-bankrupt/

B. Meiling ENDPTS
13 Mar 2018

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-january-31-2018-1517375593.pdf

FDA
31 Jan 2018

http://www.pharmatimes.com/news/final_nhs_no_for_obesity_pill_mysimba_1214102

Selina McKee PHARMA TIMES
12 Dec 2017

https://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-commercialization-and-distributorship-agreement-with-merck-kgaa-darmstadt-germany-for-contrave-in-latin-america-300554337.html

PR NEWSWIRE
13 Nov 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=210081

FDA
08 Nov 2017

https://www.pharmacompass.com/pdf/news/ema-recommends-suspension-of-medicines-due-to-unreliable-studies-from-micro-therapeutic-research-labs-1503552764.pdf

EMA
23 Aug 2017

https://www.pharmacompass.com/pdf/news/international-laboratories-llc-issues-voluntary-nationwide-recall-of-one-1-lot-of-pravastatin-sodium-tablets-usp-40mg-packaged-in-bottles-of-30-tablets-1502427855.pdf

FDA
10 Aug 2017

http://www.pharmatimes.com/news/nice_bars_obesity_pill_from_routine_nhs_use_1199805

Selina McKee PHARMA TIMES
31 Jul 2017

http://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-expansion-of-distributorship-agreement-with-biologix-fzco-for-contrave-naltrexone-hcl--bupropion-hcl-extended-release-to-egypt-300494141.html

PR NEWSWIRE
26 Jul 2017

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-5-2017-1499230453.pdf

FDA
05 Jul 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207224

FDA
04 Jul 2017

http://www.pharmatimes.com/news/nice_rejects_orexigens_weight-loss_pill_1192361

Selina McKee PHARMA TIMES
05 May 2017

https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-april-19-2017-1492575710.pdf

FDA
19 Apr 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=207479

FDA
13 Apr 2017

https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=090693

FDA
12 Apr 2017

http://www.indiainfoline.com/article/news-top-story/lupin-receives-fda-approval-lupin-receives-fda-approval-for-generic-wellbutrin-xl-tablets-117041000026_1.html

INDIAN INFOLINE
10 Apr 2017

http://www.moneycontrol.com/news/business/sun-pharma-recalls-27-lakh-bottlesantidepressantus_8430161.html

MONEY CONTROL
07 Feb 2017

http://www.prnewswire.com/news-releases/orexigen-therapeutics-announces-spanish-launch-of-mysimba-naltrexone-hcl--bupropion-hcl-prolonged-release-in-partnership-with-laboratorios-farmaceuticos-rovi-sa-300396318.html

PR NEWSWIRE
26 Jan 2017

http://www.pharmabiz.com/NewsDetails.aspx?aid=99304&sid=2

PHARMABIZ
20 Dec 2016
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY